Combination antiviral therapy with lopinavir/ritonavir, arbidol and interferon-α1b for COVID-19.
Antivir Ther
; 25(4): 233-239, 2020.
Article
in English
| MEDLINE | ID: covidwho-1256707
ABSTRACT
Since the outbreak of coronavirus disease (COVID-19) that was discovered in 2019 in Wuhan, China, no standard therapy guideline has been set despite the severity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and its high infectivity. The globally pandemic outbreak suggests that COVID-19 is highly infectious and difficult to control. A dual-combination of ribavirin and interferon-α has been the widely used regimen for the treatment of this disease in China. However, due to the varying results of treatment with these drugs, a novel antiviral combination therapy is urgently needed. This case reports the usage of lopinavir/ritonavir-based combination antiviral regimen for a patient with SARS-CoV-2 infection.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
SARS-CoV-2
/
COVID-19 Drug Treatment
Type of study:
Case report
/
Observational study
/
Prognostic study
Limits:
Adult
/
Humans
/
Male
Language:
English
Journal:
Antivir Ther
Journal subject:
Drug Therapy
/
Virology
Year:
2020
Document Type:
Article
Affiliation country:
Imp3362
Similar
MEDLINE
...
LILACS
LIS